000			02160naaaa2200277uu 4500
001			https://directory.doabooks.org/handle/20.500.12854/55772
005			20220220043118.0
020			_a/dx.doi.org/10.5771/9783845251288
020			_a9783845251288
024	7		_ahttp://dx.doi.org/10.5771/9783845251288 _cdoi
041	0		_aEnglish
042			_adc
100	1		_aDonghi, Monica _4auth
245	1	0	_aPatent Strategy in Pharmaceutical Industry: Are additional patents valuable?
260			_bNomos Verlagsgesellschaft mbH & Co. KG _c2014
300			_a1 electronic resource (84 p.)
506	0		_aOpen Access _2star _fUnrestricted online access
520			_aThis book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two “blockbuster” drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown.
540			_aCreative Commons _fhttps://creativecommons.org/licenses/by/4.0/ _2cc _4https://creativecommons.org/licenses/by/4.0/
546			_aEnglish
653			_aMarkenrecht
653			_aUrheberrecht / Gewerblicher Rechtsschutz und Medienrecht
653			_aGewerblicher Rechtsschutz
856	4	0	_awww.oapen.org _uhttps://www.nomos-elibrary.de/10.5771/9783845251288 _70 _zDOAB: download the publication
856	4	0	_awww.oapen.org _uhttps://directory.doabooks.org/handle/20.500.12854/55772 _70 _zDOAB: description of the publication
999			_c65231 _d65231